Custom Search

Search Mad Money Fund Blog

Are You Buying Jim Cramer's Get Rich Carefully Book ?

Share Stock Picks

Monday, January 18, 2010

Martin Luther King Jr. Stock Picks for 2010 ! ( TKO,GILD )

1. Taseko Mines Limited (TKO) 5.73 a share / target price 8.00
Taseko Mines Limited (Taseko) is a mining and mineral exploration company. The Company has one operating mine and three exploration projects, all located in British Columbia, Canada, which includes Gibraltar copper-molybdenum mine, the Prosperity gold-copper property, the Harmony gold property, and the Aley niobium property. On May 2, 2008, Taseko completed the acquisition of Oakmont Ventures Ltd.
approval from British Columbia's environment ministry to proceed with its Prosperity gold-copper project. Cramer say's it is a risky stock , however this is a good time to buy !

2. Gilead Sciences, Inc. (GILD) 45.18 a share / target price 60.00
Gilead Sciences, Inc. (Gilead) is a biopharmaceutical company that discovers, develops, and commercializes therapeutics in areas of unmet medical need. The Company has United States and international commercial sales operations, with marketing subsidiaries in Australia, Austria, Canada, France, Germany, Greece, Ireland, Italy, New Zealand, Portugal, Spain, Switzerland, Turkey, United Kingdom, and United States. Its commercial team promotes Truvada, Viread, Emtriva, Hepsera, AmBisome, Letairis, and Flolan through direct field contact with physicians, hospitals, clinics, and other healthcare providers. Gilead’s corporate partner, Astellas Pharma, Inc. (Astellas), promotes and sells AmBisome in the United States, Canada, Europe, Australia, and New Zealand. In May 2008, the Company acquired Navitas Assets, LLC’s. In April 2009, the Company announced the completion of its acquisition of CV Therapeutics, Inc.GILD is currently a "sleeper" as a swineflu play (they license their vaccine to La Roche); their profits in this area were quintepled last for the 3Q! They currently have a value that reflects at most 20% of what the market has seen, but continue to be a leader in their niche of medical therapies.Yes, this stock is pricey at 16.8 P/E and 6.9 book, but I think I'm getting what I pay for: plenty of cash, consistently growing sales. Margins and ROE are nearly the best in the industry.Gilead Sciences may have had its stock performance depressed by the ongoing healthcare reform. It has essentially not participated in the 2009 market rally while posting solid revenue and earnings....
Post a Comment